Commonwealth Equity Services’s 4D Molecular Therapeutics FDMT Stock Holding History

Commonwealth Equity Services’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$380K	Buy	28,574 +300	+1%	+$2.92K	﹤0.01%	3541
2026 Q1	$263K	Buy	28,274 +8,265	+41%	+$71.9K	﹤0.01%	3746
2025 Q4	$150K	Buy	+20,009	New	+$203K	﹤0.01%	4044

Other funds holding FDMT

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Commonwealth Equity Services's FDMT Position: Q2 2026 in Review

Commonwealth Equity Services increased its 4D Molecular Therapeutics (FDMT) stake by 1.1% in Q2 2026, buying an estimated $2.92K and bringing the position to 28,574 shares worth $380K. The position accounts for ﹤0.01% of the portfolio, ranked #3541.

Commonwealth Equity Services first reported a position in FDMT in Q4 2025 and has held it in 3 quarters since. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

Commonwealth Equity Services held 28,574 shares of 4D Molecular Therapeutics worth $380K as of Q2 2026.
Commonwealth Equity Services bought 300 4D Molecular Therapeutics shares in Q2 2026, an estimated $2.92K.
4D Molecular Therapeutics made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q2 2026, its #3541 holding.
Commonwealth Equity Services first reported a position in 4D Molecular Therapeutics in Q4 2025 and has held it in 3 quarters since.
158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Commonwealth Equity Services's 13F filing for Q2 2026, filed 29 Jul 2026.